Skip to main content
G

GenviewDX

GenviewDX offers comprehensive diagnostic testing services, including NGS genetic variant analysis, infectious disease detection, and toxicology screening. They provide physicians with precise, rapid test results to support personalized medicine and proactive patient care.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Physicians require accurate and timely diagnostic data to implement personalized medicine strategies and manage patient health proactively. Delays in testing or insufficient data can impede informed clinical decision-making, potentially affecting patient outcomes.

Solution

GenviewDX provides comprehensive diagnostic testing services, including genetic variant analysis via Next-Generation Sequencing (NGS), infectious disease detection, toxicology screening, and general health assessments. The company leverages advanced testing methodologies to deliver precise data with rapid turnaround times, empowering physicians to make informed clinical decisions. This approach supports the delivery of personalized medicine and facilitates proactive health management for patients.

Target Audience

The primary customers are physicians and healthcare providers who require advanced diagnostic capabilities to support personalized medicine and proactive patient care.

Features

  • Next-Generation Sequencing (NGS) for rapid genetic variant analysis.
  • Molecular testing for infectious disease detection.
  • Comprehensive toxicology screening panels.
  • General health assessment testing for a broad range of health markers.
  • CLIA-certified and COLA-accredited laboratory operations.
  • 48-hour turnaround time for test results.
  • Secure data reporting for clinical decision support.
This profile is AI-generated and may contain inaccuracies.